Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease

Griese, Matthias; Kappler, Matthias; Stehling, Florian; Schulze, Johannes; Baden, Winfried; Koerner-Rettberg, Cordula; Carlens, Julia; Prenzel, Freerk; Nährlich, Lutz; Thalmeier, Andreas; Sebah, Daniela; Kronfeld, Kai; Rock, Hans; Ruckes, Christian; Olivier, Margarete; Zielen, Stefan; Bagheri-Potthof, Azadeh; Thome, Ulrich; Gebhardt, Julia; Mehl, Anna; Lau, Susanne Gabriele; Philipp, Utz; Kopp, Matthias; Stichtenoth, Guido; Sommerburg, Olaf; Stahl, Mirjam; Kitz, Richard; Rietschel, Christoph; Stock, Philippe; Ahrens, Frank; Hebestreit, Helge; Segerer, Florian; Brinkmann, Folke; Anne, Schlegtendal; Eismann, Claudia; Neuner, Dörthe; Witt, Sabine; Hengst, Meike; Feilcke, Maria; Babl, Jürgen; Stauffer, Gabriele; Nickolay, Tanja; Gorbulev, Stanislav; Anthony, Gisela; Stöhr, Linda; Vieweg, Laura; Strenge-Hesse, Anke; Wetzke, Martin; Seidl, Elias und Schwerk, Nicolaus (23. Juli 2022): Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease. In: Orphanet Journal of Rare Diseases, Bd. 17

Abstract

Background No results of controlled trials are available for any of the few treatments offered to children with interstitial lung diseases (chILD). We evaluated hydroxychloroquine (HCQ) in a phase 2, prospective, multicentre, 1:1-randomized, double-blind, placebo-controlled, parallel-group/crossover trial. HCQ (START arm) or placebo were given for 4 weeks. Then all subjects received HCQ for another 4 weeks. In the STOP arm subjects already taking HCQ were randomized to 12 weeks of HCQ or placebo (= withdrawal of HCQ). Then all subjects stopped treatment and were observed for another 12 weeks.

Results 26 subjects were included in the START arm, 9 in the STOP arm, of these four subjects participated in both arms. The primary endpoint, presence or absence of a response to treatment, assessed as oxygenation (calculated from a change in transcutaneous O 2 -saturation of ≥ 5%, respiratory rate ≥ 20% or level of respiratory support), did not differ between placebo and HCQ groups. Secondary endpoints including change of O 2 -saturation ≥ 3%, health related quality of life, pulmonary function and 6-min-walk-test distance, were not different between groups. Finally combining all placebo and all HCQ treatment periods did not identify significant treatment effects. Overall effect sizes were small. HCQ was well tolerated, adverse events were not different between placebo and HCQ.

Conclusions Acknowledging important shortcomings of the study, including a small study population, the treatment duration, lack of outcomes like lung function testing below age of 6 years, the small effect size of HCQ treatment observed requires careful reassessments of prescriptions in everyday practice (EudraCT-Nr.: 2013-003714-40, www.clinicaltrialsregister.eu , registered 02.07.2013).

• Dokumententyp: Zeitschriftenartikel
• Publikationsform: Publisher's Version
• Fakultät: Medizin > Klinikum der LMU München > Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 1750-1172
• Sprache: Englisch
• DFG: Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 491502892